These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11561681)

  • 1. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
    Whitehead RP; Unger JM; Flaherty LE; Eckardt JR; Taylor SA; Didolkar MS; Samlowski W; Sondak VK
    Invest New Drugs; 2001; 19(3):239-43. PubMed ID: 11561681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
    Pazdur R; Meyers C; Diaz-Canton E; Abbruzzese JL; Patt Y; Grove W; Ajani J
    Am J Clin Oncol; 1997 Dec; 20(6):573-6. PubMed ID: 9391543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
    Whitehead RP; Unger JM; Flaherty LE; Kraut EH; Mills GM; Klein CE; Chapman RA; Doolittle GC; Hammond N; Sondak VK;
    Invest New Drugs; 2002 Feb; 20(1):105-11. PubMed ID: 12003185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
    Kunschner LJ; Fine H; Hess K; Jaeckle K; Kyritsis AP; Yung WK
    Cancer Invest; 2002; 20(7-8):948-54. PubMed ID: 12449727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CI-980 in advanced melanoma and hormone refractory prostate cancer.
    Ryan CW; Shulman KL; Richards JM; Kugler JW; Sosman JA; Ansari RH; Vokes EE; Vogelzang NJ
    Invest New Drugs; 2000 May; 18(2):187-91. PubMed ID: 10857996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.
    Patel SR; Burgess MA; Papadopolous NE; Sidhu G; Gray R; Plager C; Jenkins J; Benjamin RS
    Invest New Drugs; 1998; 16(1):87-92. PubMed ID: 9740549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
    Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
    Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
    Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
    Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
    Thomas JP; Moore T; Kraut EH; Balcerzak SP; Galloway S; Vandre DD;
    Cancer Invest; 2002; 20(2):192-8. PubMed ID: 11901539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
    Sklarin NT; Lathia CD; Benson L; Grove WR; Thomas S; Roca J; Einzig AI; Wiernik PH
    Invest New Drugs; 1997; 15(3):235-46. PubMed ID: 9387046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
    Kudelka AP; Hasenburg A; Verschraegen CF; Edwards CL; Meyers CA; Varma D; Freedman RS; Forman A; Conrad CA; Grove W; Grothey A; Kavanagh JJ
    Anticancer Drugs; 1998 Jun; 9(5):405-9. PubMed ID: 9660537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
    Li T; Christensen SD; Frankel PH; Margolin KA; Agarwala SS; Luu T; Mack PC; Lara PN; Gandara DR
    Invest New Drugs; 2012 Apr; 30(2):741-8. PubMed ID: 20967484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of amonafide in disseminated malignant melanoma. A Southwest Oncology Group study.
    Slavik M; Kopecky KJ; Sondak V; Craig JB; Samson MK
    Invest New Drugs; 1993; 11(2-3):223-6. PubMed ID: 8262736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
    Sosman JA; Flaherty LE; Liu PY; Fletcher W; Thompson JA; Hantel A; Sondak V
    Invest New Drugs; 1995; 13(1):83-7. PubMed ID: 7499114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.
    Sondak VK; Kopecky KJ; Liu PY; Fletcher WS; Harvey WH; Laufman LR
    Anticancer Drugs; 1994 Apr; 5(2):147-50. PubMed ID: 8049497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
    Rowinsky EK; Long GS; Noe DA; Grochow LB; Bowling MK; Sartorius SE; Donehower RC
    Clin Cancer Res; 1997 Mar; 3(3):401-7. PubMed ID: 9815698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921).
    Flaherty LE; Liu PY; Mitchell MS; Fletcher WS; Walker MJ; Goodwin JW; Stephens RL; Sondak VK
    Am J Clin Oncol; 1996 Apr; 19(2):108-13. PubMed ID: 8610631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.